System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study) (MOODY)
Sponsor: Nanjing First Hospital, Nanjing Medical University
This observational or N/A phase trial investigates Coronary Heart Disease and is currently completed. Nanjing First Hospital, Nanjing Medical University leads this study, which shows 10 recorded versions since 1999 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Completed NA
Status: Enrolling By Invitation → Completed
-
Jul 2017 — Dec 2017 [monthly]
Enrolling By Invitation NA
-
Mar 2017 — Jul 2017 [monthly]
Enrolling By Invitation NA
-
Feb 2017 — Mar 2017 [monthly]
Enrolling By Invitation NA
First recorded
Jan 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing First Hospital, Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anqing, China , Bengbu, China , Changshu, China , Changzhou, China , Huai'an, China , Huainan, China , Jintan, China , Liyang, China , Ma’anshan, China , Muyang, China and 5 more locations